Chemistry: analytical and immunological testing – Involving an insoluble carrier for immobilizing immunochemicals
Reexamination Certificate
2004-07-13
2009-06-09
Rao, Manjunath (Department: 1647)
Chemistry: analytical and immunological testing
Involving an insoluble carrier for immobilizing immunochemicals
C436S007000, C436S007000
Reexamination Certificate
active
07544519
ABSTRACT:
The present invention provides a purified polynucleotide encoding a novel polypeptide, designated Fhm, which belongs to the TNF gene superfamily; to purified Fhm polypeptide molecules; to antibodies that bind Fhm; to materials comprising such molecules; and to methods of using such molecules.
REFERENCES:
patent: 5312733 (1994-05-01), MacLeod
patent: 5489743 (1996-02-01), Robinson et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5843789 (1998-12-01), Nomura et al.
patent: 5863769 (1999-01-01), Young
patent: 5885800 (1999-03-01), Emery et al.
patent: 6271366 (2001-08-01), Kimura et al.
patent: 6274339 (2001-08-01), Moore et al.
patent: 6599719 (2003-07-01), Yu et al.
patent: 6627199 (2003-09-01), Saris
patent: 6764679 (2004-07-01), Ashkenazi et al.
patent: 6824767 (2004-11-01), Yu et al.
patent: 2002/0111325 (2002-08-01), Li et al.
patent: 2002/0150534 (2002-10-01), Yu et al.
patent: 2002/0150583 (2002-10-01), Gentz et al.
patent: 2003/0027284 (2003-02-01), Yu et al.
patent: 2003/0082736 (2003-05-01), Smith
patent: 2003/0096355 (2003-05-01), Zhang
patent: 2003/0129189 (2003-07-01), Yu et al.
patent: 2003/0198640 (2003-10-01), Yu et al.
patent: 2004/0013664 (2004-01-01), Gentz et al.
patent: 19809978 (1999-09-01), None
patent: 0648783 (1995-04-01), None
patent: 0861850 (1998-09-01), None
patent: WO-93/19777 (1993-10-01), None
patent: WO-94/06476 (1994-03-01), None
patent: WO-96/14328 (1996-05-01), None
patent: WO-96/37609 (1996-11-01), None
patent: WO-98/30694 (1998-07-01), None
patent: WO-98/35986 (1998-08-01), None
patent: WO-98/43998 (1998-10-01), None
patent: WO-99/03992 (1999-01-01), None
patent: WO-99/04001 (1999-01-01), None
patent: WO-99/06426 (1999-02-01), None
patent: WO-99/07738 (1999-02-01), None
patent: WO-99/11791 (1999-03-01), None
patent: WO-99/14330 (1999-03-01), None
patent: WO-99/20758 (1999-04-01), None
patent: WO-99/23105 (1999-05-01), None
patent: WO-99/26977 (1999-06-01), None
patent: WO-99/31128 (1999-06-01), None
patent: WO-99/35268 (1999-07-01), None
patent: WO-99/50413 (1999-10-01), None
patent: WO-99/51744 (1999-10-01), None
patent: WO-00/08139 (2000-02-01), None
patent: WO-00/18800 (2000-04-01), None
Pitti et al., Nature. Dec. 17, 1998;396:699-703.
Harlow et al., Antibodies, A Laboratory Manual. 1988. Cold Spring Harbor Laboratory, p. 241.
Zhang et al: “Modulation of T-cell responses to alloantigens by TR6/DcR3,” J. Clin. Invest. 107:1459-1468 (2003).
Aderka “The Potential Biological and Clinical Significance of the Soluble Tumor Necrosis Factor Receptors” Cytokine & Growth Factor Reviews, 7(3):231-240 (1996).
Aggarwal et al. “Characterization of Receptors for Human Tumor Necrosis Factor and their Regulation By Gamma Interferon” Nature, 318:665-667(1985).
Ausubel et al. eds., Transfection of DNA Into Eukaryotic Cells in Current Protocols in Molecular Biology, Section 9.1.1 9.1.3, John Wiley & Sons, New York 1996.
Baker et al. “Transducers of Life and Death: TNF Receptor Superfamily and Associated Proteins” Oncogene, 12(1):1-9 (1996).
Bamias et al. “Expression, Localization, and Functional Activity of TL1A, a Novel Th1-Polarizing Cytokine in Inflammatory Bowel Disease” J. of Immunol., 171:4868-4874 (2003).
Beyaert et al. Tumor Necrosis Factor and Lymphokines in: Cytokines eds. Anthony Mire Sluis and Robin Thorpe, Academic Press San Diego CA, 1998.
Browning et al. “Lymphotoxin Beta, a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface” Cell, 72:847 856 (1993).
Bucay et al. “Osteoprotegerin-Deficient Mice Develop Early Onset Osteoporosis and Arterial Calcification” Genes & Development, 12:1260-1268 (1998).
Chen et al. “Quantification and Detection of DcR3, a Decoy Receptor in TNFR Family” J. of Immunol. Meth., 285:63-70 (2004).
Chew et al. “A Novel Secreted Splice Variant of Vascular Endothelial Cell Growth Inhibitor” FASEB J., 16:742-744 (2002).
Connolly et al. “In Vivo Inhibition of Fas Ligand-Mediated Killing by TR6, a Fas Ligand Decoy Receptor” Journal of Pharmacology and Experimental Therapeutics, 298(1):25-33 (2001).
Degli-Esposti “To Die or Not to Die—The Quest of the TRAIL Receptors” Journal of Leukocyte Biology, 65:535-542 (1999).
Degli-Esposti et al. “Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family” J. Exp. Med. 186(7):1165-1170 (1997).
Degli-Esposti et al. “The Novel Receptor TRAIL-R4 Induces NF-kb and Protects Against TRAIL-Mediated Apoptosis, yet Retains and Incomplete Death Domain” Immunity, 7: 813-820 (1997).
Emery et al. “Osteoprotegerin is a Receptor for the Cytotoxic Ligand TRAIL” J. of Biol. Chem., 273(23):14363-14367 (1998).
Fernandez-Botran “Soluble Cytokine Receptors: Their Role In Immunoregulation” FASB J., 5:2567-2574 (1991).
Fisher, Production of Antibody in Radioimmunoassay in ; Manual of Clinical Immunology, 2d Ed. (Rose and Friedman, eds.) Amer. Soc. For Microbiol., Washington, D.C., 1980.
Gill et al. “Differential Expression of Light and Its Receptors in Human Placental Villi and Amniochorion Membranes” American Journal of Pathology, 161(6):2011-2017 (2002).
Griffith et al. “Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies” J. of Immunol., 162(5):2597-2605 (1999).
Griffith et al. “Monocyte-Mediated Tumoricidal Activity via the Tumor Necrosis Factor-related Cytokine, TRAIL” J. Exp. Med. 189(8):1343-1354 (1999).
Griffith et al. “TRAIL: a Molecule with Multiple Receptors and Control Mechanisms” Curr. Opin. Immnunol. 10(5):559-563 (1998).
Hofmann “The Modular Nature of Apoptotic Signaling Proteins” CMLS, 55:1113-1128 (1999).
Hsu et al. “Enhanced Adhesion of Monocytes Via Reverse Signaling Triggered by Decoy Receptor 3” Experimental Cell Research, 292:241-251 (2004).
Kim et al. “Selective Induction of Tumor Necrosis Receptor factor 6/Decoy Receptor 3 Release by Bacterial Antigens in Human Monocytes and Myeloid Dendritic Cells” Infection and Immunity, 72(1):89-93 (2004).
Marsters et al. “A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain” Current Biology, 7(12):1003-1006 (1997).
McFarlane et al. “Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL” J. Biol. Chem., 272(41): 25417-25420 (1997).
Meurs et al. “Tumor Suppressor Function of the Interferon-Induced Double-Stranded RNA-Activated Protein Kinase” Proc. Natl. Acad. Sci. USA, 90:232-236 (1993).
Migone et al. “TL1A is a TNF-Like Ligand for DR3 and TR6/DcR3 and Functions as a T Cell Costimulator” Immunity, 16:479-492 (2002).
Moult “The Current State of the Art in Protein Structure Prediction” Curr. Op. in Biotech., 7(4):422 427 (1996).
Naismith et al. “Modularity in the TNF-Receptor Family” TIBS 23:74-79 (1998).
Nophar et al. “Soluble Forms of Tumor Necrosis Factor Receptors (TNF Rs). The cDNA for the Type I TNF-R, Cloned Using Amino Acid Sequence Data of its Soluble Form, Encodes Both the Cell Surface and a Soluble Form of the Receptor” EMBOJ., 9(10):3269-3278 (1990).
Orlinick et al. “TNF Related Ligands and Their Receptors” Cell Signal, 10(8):543-551 (1998).
Ouchterlony et al., Immunodiffusion and Immunoelectrophoresis in: Handbook of Experimental Immunology ed. D. Weir, Blackwell, 1973.
Pan et al. “An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL” Science, 277:815-818 (1997).
Pan et al. “The Receptor for the Cytotoxic Ligand TRAIL” Science, 276:111-113 (1997).
Pan et al. “TRUNDD, a New Member of the TRAIL Receptor Family that Antagonizes TRAIL Signalling” FEBS Letters 424:41-45 (1998).
Perry et al. “Characterization of Proximal Colonic Lymphoid Tissue in the Mouse” The Anatomical Re
Boyle William James
Hsu Hailing
Wooden Scott Kenneth
Amgen Inc.
Marshall & Gerstein & Borun LLP
Rao Manjunath
Woodward Cherie
LandOfFree
Fhm a novel member of the TNF ligand supergene family:... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fhm a novel member of the TNF ligand supergene family:..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fhm a novel member of the TNF ligand supergene family:... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4076401